The Challenge of Assessing Obstructive Coronary Artery Disease1-5
According to current ACC/AHA estimates, there may be as many as 16.5 million stable angina patients in the United States, with 500,000 new diagnoses annually. Despite advances in imaging technology, non-invasive assessment of obstructive coronary artery disease (CAD) continues to be challenging. The complexity of CAD assessment lies not only in the variation of presenting symptoms, but also in the patient’s unique characteristics. Moreover, implementation of standard of care involving non-invasive imaging assessment of CAD is highly variable regarding the type, number, and sequence of tests to be performed.
What is Corus™ CAD?
The Corus CAD gene expression test is an entirely new way to assess obstructive* CAD in patients with chest pain.
- Delivering on the promise of genomic medicine, Corus CAD provides a clinically actionable gene expression test that empowers cardiologists to make more informed patient care decisions
- Assessing a patient’s disease at the molecular level, Corus CAD provides quantitative information about the likelihood that an individual patient has obstructive CAD
- Validated in a rigorous multi-center trial, Corus CAD integrates the expression levels of 23 genes and other patient characteristics that have been demonstrated to indicate obstructive CAD
- Corus CAD only requires a standard blood draw procedure, and the objective results are promptly delivered to the physician
For Which Patients?
Corus CAD is intended for use in patients who:
- Present with stable chest pain, typical or atypical angina or anginal equivalent
- Have no previous diagnosis of myocardial infarction (MI)
- Have not had a revascularization procedure
- Do not have diabetes
- Have no inflammatory or infectious conditions
- Are not currently taking steroids, immunosuppressive agents, or chemotherapeutic agents
* Obstructive CAD is defined as at least one atherosclerotic plaque causing ≥50% luminal diameter stenosis in a major coronary artery (≥1.5 mm lumen diameter) as determined by invasive quantitative coronary angiography (QCA).
- Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003;41(1):159-168.
- Lloyd-Jones D, Adams R, Carnethon M, et al. for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480-486.
- Anderson JL. Beyond Framingham: contemporary evolution of individualized coronary heart disease risk assessment. Available at: http://www.medscape.com/infosite/cardiodx/article-2. Accessed on May 19, 2009.
- Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol. 2003;41(9):1475-1479.
- Lauer MS. Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. JAMA. 2007;297(12):1376-1378. Epub 2007 Mar 25.
